Shareholder letter...
Shareholder letter...
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology. TriKE® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
May 21, 2024 • 9:15 EDT | Read More
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 15, 2024 • 5:00 EDT | Read More